Skip to main content
AAPS Open
Fig. 6 | AAPS Open

Fig. 6

From: Extraction of niclosamide from commercial approved tablets into aqueous buffered solution creates potentially approvable oral and nasal sprays against COVID-19 and other respiratory infections

Fig. 6

Yomesan-niclosamide equivalent concentrations of 300 µM, 600 µM, and 1 mM in nominal 9.34 TB (0–day 2). Final pHs were ~ 9.2. Peak concentrations: 171.7 µM, 215.8 µM, and 264.2 µM; day 2 concentrations: 143.8 µM, 104.4 µM, and 88.7 µM respectively; average day 2 value = 112.3 µM ± 28.4 µM

Back to article page